EyePoint Pharmaceuticals, Inc.
EYPT
$14.52
$0.836.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -103.44% | -92.78% | -54.33% | -193.63% | -132.80% |
| Total Depreciation and Amortization | 41.18% | 48.62% | 64.03% | 316.96% | 254.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.67% | -20.25% | -49.79% | 96.13% | 55.15% |
| Change in Net Operating Assets | 63.73% | -382.85% | -1.36% | 91.06% | -148.45% |
| Cash from Operations | -52.08% | -210.18% | -70.41% | -55.13% | -156.70% |
| Capital Expenditure | 49.30% | -35.56% | 76.88% | 56.51% | 8.49% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 216.17% | 131.07% | 80.91% | -106.59% | -- |
| Cash from Investing | 241.97% | 130.14% | 89.97% | -103.53% | 1,041.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 63.01% | -- | -- | -- | -- |
| Issuance of Common Stock | -37.21% | -56.32% | -87.00% | -30.40% | 11.76% |
| Repurchase of Common Stock | -70.51% | 75.64% | 72.04% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -226.97% | -913.89% | 100.00% |
| Cash from Financing | -37.75% | -27.66% | -926.96% | -30.57% | 14.78% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 131.39% | 92.22% | -41.91% | -86.59% | -66.70% |